Imipramine: a model substance in pharmacokinetic research
by
Gram LF.
Department of Clinical Pharmacology,
Odense University.
Acta Psychiatr Scand Suppl. 1988;345:81-4

ABSTRACT

The pharmacokinetics of imipramine have been studied over a period of 20 years. Imipramine is rapidly and almost completely metabolized with the formation of desipramine (desmethylation), 2-hydroxy metabolites and subsequent glucoronide coupling. Imipramine has a high clearance (0.8-1.5 l/min) and a corresponding high first pass elimination (30-70%). Volume of distribution is high (650-1100 1) and half-lives accordingly of medium length (6-12 h). The 2-hydroxylation which is the most important step of elimination is mediated via microsomal cytochrome P450 isozyme that exhibit monogenetic polymorphism such that 5-10% of the population have a severely reduced clearance. Co-administration of neuroleptics may also considerably impair the 2-hydroxylation. Steady-state levels of imipramine and desipramine varies considerably among individuals mainly due to variations in metabolism, but also to a smaller extent due to variations in binding to plasma proteins. The variations in steady-state concentrations appear to have clear implication for the clinical effects of imipramine.

Imipramine
Desipramine
TCAs v SSRIs
Antidepressants
Retarded depression
Selectivity or multiplicity?
Imipramine and enkephalin
Imipramine and depression
Noradrenaline and dopamine
Imipramine and dopamine d1
Imipramine v DL-phenylalanine
Zinc, imipramine and depression
Imipramine (Tofranil) restores appetitive behavior

Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family